Surface immunogenic protein from Streptococcus agalactiae and
Humans
Toll-Like Receptor 4
/ metabolism
Myeloid Differentiation Factor 88
/ metabolism
Hemocyanins
/ metabolism
Streptococcus agalactiae
Ligands
Membrane Proteins
/ metabolism
Adjuvants, Vaccine
Signal Transduction
Adaptor Proteins, Signal Transducing
/ metabolism
Adjuvants, Immunologic
/ pharmacology
Adaptor Proteins, Vesicular Transport
/ metabolism
MyD88
TLR4 agonist
TRIF
antigen-presenting cells
hemocyanin from Fissurella latimarginata (FLH)
protein-based adjuvants (PBAs)
recombinant surface immunological protein from Streptococcus agalactiae (rSIP)
vaccines
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
03
2023
accepted:
29
08
2023
medline:
5
10
2023
pubmed:
4
10
2023
entrez:
4
10
2023
Statut:
epublish
Résumé
The development of vaccine adjuvants is of interest for the management of chronic diseases, cancer, and future pandemics. Therefore, the role of Toll-like receptors (TLRs) in the effects of vaccine adjuvants has been investigated. TLR4 ligand-based adjuvants are the most frequently used adjuvants for human vaccines. Among TLR family members, TLR4 has unique dual signaling capabilities due to the recruitment of two adapter proteins, myeloid differentiation marker 88 (MyD88) and interferon-β adapter inducer containing the toll-interleukin-1 receptor (TIR) domain (TRIF). MyD88-mediated signaling triggers a proinflammatory innate immune response, while TRIF-mediated signaling leads to an adaptive immune response. Most studies have used lipopolysaccharide-based ligands as TLR4 ligand-based adjuvants; however, although protein-based ligands have been proven advantageous as adjuvants, their mechanisms of action, including their ability to undergo structural modifications to achieve optimal immunogenicity, have been explored less thoroughly. In this work, we characterized the effects of two protein-based adjuvants (PBAs) on TLR4 signaling via the recruitment of MyD88 and TRIF. As models of TLR4-PBAs, we used hemocyanin from
Identifiants
pubmed: 37790926
doi: 10.3389/fimmu.2023.1186188
pmc: PMC10544979
doi:
Substances chimiques
Toll-Like Receptor 4
0
Myeloid Differentiation Factor 88
0
Hemocyanins
9013-72-3
Ligands
0
Membrane Proteins
0
Adjuvants, Vaccine
0
Adaptor Proteins, Signal Transducing
0
Adjuvants, Immunologic
0
Adaptor Proteins, Vesicular Transport
0
TLR4 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1186188Informations de copyright
Copyright © 2023 Díaz-Dinamarca, Salazar, Escobar, Castillo, Valdebenito, Díaz, Manubens, Salazar, Troncoso, Lavandero, Díaz, Becker and Vásquez.
Déclaration de conflit d'intérêts
Authors AM, FS and MIB were employed by BIOSONDA S.A. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Immunol. 2019 May 31;10:1136
pubmed: 31214162
Nat Rev Immunol. 2014 Aug;14(8):546-58
pubmed: 25060580
Biomedicines. 2019 Jun 03;7(2):
pubmed: 31163699
iScience. 2020 Feb 21;23(2):100881
pubmed: 32062450
J Biomed Mater Res A. 2007 Jun 1;81(3):652-62
pubmed: 17187395
FEBS Lett. 2009 Dec 17;583(24):3966-73
pubmed: 19850042
Cell Mol Life Sci. 2008 Oct;65(20):3231-40
pubmed: 18668203
Br J Cancer. 2019 Oct;121(9):786-795
pubmed: 31588122
Curr Opin Immunol. 2016 Aug;41:85-90
pubmed: 27392183
Cell. 2014 Jul 31;158(3):506-21
pubmed: 25083866
Sci Rep. 2016 Feb 24;6:22064
pubmed: 26907999
J Immunol. 2016 Jun 1;196(11):4650-62
pubmed: 27183578
Sci Signal. 2015 Jul 14;8(385):ra69
pubmed: 26175492
Mol Immunol. 2019 Jul;111:198-204
pubmed: 31078966
J Biol Chem. 2019 Dec 20;294(51):19546-19564
pubmed: 31719148
Nat Rev Drug Discov. 2021 Jun;20(6):454-475
pubmed: 33824489
Science. 2003 Aug 1;301(5633):640-3
pubmed: 12855817
Vaccines (Basel). 2014 Apr 25;2(2):323-53
pubmed: 26344622
PLoS One. 2014 Jan 23;9(1):e87240
pubmed: 24466345
Trends Pharmacol Sci. 2017 Sep;38(9):771-793
pubmed: 28668223
Curr Opin Immunol. 2020 Aug;65:97-101
pubmed: 33038865
Sci Signal. 2016 Aug 30;9(443):ra86
pubmed: 27577261
Front Immunol. 2022 Aug 01;13:940047
pubmed: 35979365
Vaccine. 2011 Apr 12;29(17):3341-55
pubmed: 20713100
Front Immunol. 2020 Oct 16;11:577823
pubmed: 33178204
Vaccines (Basel). 2020 Mar 26;8(2):
pubmed: 32224855
J Vis Exp. 2011 Dec 26;(58):e3179
pubmed: 22231636
J Immunol Methods. 1999 Feb 1;223(1):77-92
pubmed: 10037236
J Immunol. 2011 May 15;186(10):5772-83
pubmed: 21498664
Biochem Soc Trans. 1976;4(2):307-9
pubmed: 1001673
Mol Biotechnol. 2018 Mar;60(3):215-225
pubmed: 29442290
Eur J Immunol. 2021 Jul;51(7):1715-1731
pubmed: 33891704
Micron. 2004;35(1-2):21-2
pubmed: 15036282
Br J Cancer. 2013 Sep 17;109(6):1488-97
pubmed: 23989944
Mol Immunol. 2018 Nov;103:63-70
pubmed: 30205305
Nature. 2010 Jun 17;465(7300):885-90
pubmed: 20485341
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32690772
Nature. 2001 Jul 19;412(6844):346-51
pubmed: 11460167
Nat Rev Genet. 2012 Mar 13;13(4):227-32
pubmed: 22411467
Sci Signal. 2012 Feb 14;5(211):ra13
pubmed: 22337809
Pharmaceutics. 2022 Aug 11;14(8):
pubmed: 36015297
Mol Biosyst. 2009 Dec;5(12):1512-26
pubmed: 20023718
Front Immunol. 2020 Jul 10;11:1210
pubmed: 32765484
Sci Signal. 2017 Oct 31;10(503):
pubmed: 29089449
Vaccines (Basel). 2020 Jan 16;8(1):
pubmed: 31963234
Science. 2007 Jun 15;316(5831):1628-32
pubmed: 17569868
Sci Signal. 2014 Nov 11;7(351):ra108
pubmed: 25389373
Eur J Immunol. 2013 Sep;43(9):2398-408
pubmed: 23716300
Science. 2018 Nov 9;362(6415):694-699
pubmed: 30409884
J Biol Chem. 2004 Jun 18;279(25):26134-42
pubmed: 15075320
Immunity. 2015 May 19;42(5):850-63
pubmed: 25979419
Eur J Immunol. 2004 Feb;34(2):398-407
pubmed: 14768044
Front Microbiol. 2015 Mar 31;6:261
pubmed: 25873917
Oncotarget. 2016 Jun 21;7(25):38451-38466
pubmed: 27224911
Immunity. 2015 Dec 15;43(6):1087-100
pubmed: 26682983
Small GTPases. 2020 May;11(3):211-219
pubmed: 28960134
Front Immunol. 2019 May 29;10:1144
pubmed: 31191528
Nat Rev Immunol. 2018 Oct;18(10):635-647
pubmed: 30057419
EMBO Rep. 2016 Dec;17(12):1753-1765
pubmed: 27861124
Immunity. 1999 Jul;11(1):115-22
pubmed: 10435584
Front Immunol. 2018 Jun 14;9:1231
pubmed: 29963041
Mol Pharmacol. 2011 Jan;79(1):34-41
pubmed: 20881006